Papilledema is a very rare complication of leukemia therapies, and particularly tyrosine kinase inhibitor (TKI) therapy. Targeted oncologic therapies are becoming increasingly popular, so it is increasingly important to report rare adverse effects. We present a case of probable papilledema in the setting of ponatinib therapy for acute lymphoblastic leukemia. Our patient is a 48-year-old male who was diagnosed with acute lymphocytic leukemia. He underwent stem cell transplantation and shortly after was placed on ponatinib therapy. After initiation of ponatinib, he began to note decreased clarity in the inferonasal visual field of his right eye, corroborated on Humphrey visual field (HVF) testing. Neuroimaging was only notable for a partially empty sella. Lumbar puncture demonstrated opening pressures at the upper limit of normal (23 cm H2O) but with normal cellular constituents and chemistry. Slit lamp exam did not reveal any signs of ocular inflammation. Dilated funduscopic examination (DFE) revealed 360-degree blurring of the right optic disc margin as well as 270-degree blurring of the left optic disc (sparing the temporal border). Optical coherence tomography of the retinal nerve fiber layer (OCT-RNFL) showed increased RNFL thickness of 272 μm in the right eye and 113 μm in the left eye. In the absence of evidence for other possible etiologies of optic disc edema, ponatinib-induced papilledema was suspected. No changes to the ponatinib regimen were made; however, the patient was started on acetazolamide 500 mg twice a day. At three-month follow up, the patient reported resolution of his right eye blurriness and his repeat HVF, OCT-RNFL, and DFE showed resolution of optic disc edema, supporting that his initial bilateral optic disc swelling was likely ponatinib-induced papilledema. This is the first report of probable ponatinib-induced papilledema. This case expands on the literature of TKI induced papilledema and demonstrates successful treatment with an oral acetazolamide regimen.
Purpose: The volume of residency applications and data per applicant are increasing with emphasis on holistic review and application inflation. Studies have shown artificial intelligence (AI) could augment human review in resident selection and reveal successful candidates who may otherwise be overlooked. This study determines whether AI successfully predicts match outcomes for ophthalmology residents and could be a valid means of improving the objectivity and efficiency of the residency match process. Method: This was a prospective study of 642 applicants in the 2023-2024 San Francisco Match cycle. A total of 129 US doctors of ophthalmology and foreign medical graduates were excluded from analysis. The application data of the 513 US medical doctor graduates was studied to predict their match outcomes. Data were received from applicants on September 1, 2023, and were prospectively analyzed by both AI and faculty until the match results were released on February 6, 2024. Faculty utilized a standardized rubric to generate a rank list. In late September 2024, GPT 3.5 Turbo (Azure OpenAI) was given 5 main criteria and no prior examples to prevent bias. Both faculty and AI had access to the entire San Francisco Match application. Main outcome was predictiveness of rank list on match outcome of each applicant. Results: Both the AI rank list and faculty rank list were predictive of matching to an ophthalmology residency spot ( P values < .001). Each 10-percentile increase of the AI ranking had a 23% increase in the odds of a match (odds ratio = 1.23; 95% CI, 1.15-1.32), and each 10-percentile increase of the faculty rank list had a 41% increase in the odds of a match (odds ratio = 1.41; 95% CI, 1.29-1.53). Conclusions: AI accurately predicts match outcomes and can be used as an adjunct aide to faculty review of applications to reduce the immense administrative workload and human bias.
21 February 2023 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immune-related adverse events (IRAEs), including orbitopathy. To date, only a handful of cases have described the treatment of thyroid eye disease secondary to mAbs, and even fewer have described how to treat refractory disease. Case Presentation: We are illustrating two cases in this report: a 73-year-old woman who developed thyroid eye disease (TED) after nivolumab therapy for melanoma, and a 36-year-old man who presented with TED following alemtuzumab treatment for multiple sclerosis. Both patients failed corticosteroid therapy but showed a significant improvement with teprotumumab, an anti-insulin-like growth factor (IGF)-1 receptor mAb. Conclusions: These cases highlight underrecognized orbital IRAEs linked to mAb therapy and demonstrate teprotumumab’s potential as an effective option for steroid-refractory thyroid orbitopathy. Clinicians should maintain an awareness of orbital complications in patients receiving mAbs to enable prompt diagnosis and intervention, minimizing visual morbidity. Further studies are needed to clarify the pathogenesis of mAb-associated orbitopathy and to establish evidence-based treatment protocols for these rare but impactful complications.